PRF Technologies (PRFX) EPS (Weighted Average and Diluted) (2020 - 2024)
PRF Technologies (PRFX) recorded quarterly EPS (Weighted Average and Diluted) of -$116.31 in Q2 2024, up 94.32% on a QoQ basis from -$2046.0 in Q1 2024, and up 78.03% year-over-year from -$65.33 in Q3 2023.
PRF Technologies (PRFX) EPS (Weighted Average and Diluted) (2020 - 2024) Analysis & Trends
PRF Technologies has disclosed EPS (Weighted Average and Diluted) across 5 years of filings, most recently posting -$116.31 for Q2 2024.
- Quarterly EPS (Weighted Average and Diluted) rose 78.03% year-over-year to -$116.31 in Q2 2024, while the trailing twelve-month figure through Dec 2025 was -$11.34 (up 90.49% YoY) and the FY2025 annual result came in at -$7.47, up 92.92% from the prior year.
- EPS (Weighted Average and Diluted) improved to -$116.31 in Q2 2024, from -$2046.0 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.21 in Q4 2020 and troughed at -$10450.0 in Q1 2022.
- A 5-year average of -$1822.2 and a median of -$466.22 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- Annual changes were most pronounced in 2021 — EPS (Weighted Average and Diluted) tumbled 12669.23% — and 2023, when it jumped 89.49%.
- Tracing PRFX's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.21 in 2020, then plunged by 717.68% to -$1.74 in 2021, then sank by 1249.26% to -$23.5 in 2022, then sank by 99.53% to -$46.89 in 2023, then sank by 148.04% to -$116.31 in 2024.
- Business Quant data shows PRFX's EPS (Weighted Average and Diluted) at -$116.31 in Q2 2024, -$2046.0 in Q1 2024, and -$46.89 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | PRF Technologies | 933,081.16 | -2.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -116.31 |
| Mar 31, 2024 | -2,045.96 |
| Dec 31, 2023 | -46.89 |
| Sep 30, 2023 | -356.32 |
| Jun 30, 2023 | -529.37 |
| Mar 31, 2023 | -1,098.58 |
| Dec 31, 2022 | -23.50 |
| Sep 30, 2022 | -403.08 |
| Jun 30, 2022 | -567.69 |
| Mar 31, 2022 | -10,450.00 |
| Dec 31, 2021 | -1.74 |
| Sep 30, 2021 | -3,101.75 |
| Jun 30, 2021 | -4,256.41 |
| Mar 31, 2021 | -8,873.91 |
| Dec 31, 2020 | -0.21 |
| Sep 30, 2020 | -318.18 |
| Jun 30, 2020 | -33.33 |
| Mar 31, 2020 | -576.45 |